Minimum inhibitory concentrations of amphotericin B, clotrimazole and 5-fluorocytosine have been determined against 413 yeast strains isolated from clinical material. All 343 strains of Candida albicans were inhibited by 4 μg/ml of amphotericin B and by 16 μg/ml of clotrimazole, while 40 (11·7%) were resistant (MIC≥ 50 μg/ml) to 5-fluorocytosine. The 53 strains of Torulopsis glabrata were more sensitive to amphotericin B and less sensitive to clotrimazole than were the C. albicans strains, and 14 (24%) were resistant to 5-fluorocytosine. At concentrations of the drugs attainable in vivo (2–3, 3 and 100 μg/ml respectively), 83·4%, 16·7% and 89% of all the strains isolated would be inhibited by amphotericin B, clotrimazole and 5-fluorocytosine. From these in vitro results, it is possible that 5-fluorocytosine may show greater activity in vivo than clotrimazole against yeasts responsible for candidiasis in humans.
No takes yet. Share an insight, caveat, or question.
J. M. T. Hamilton‐Miller (1972) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: